3. Ergebnisse
3.5 Tabellarische Zusammenfassung der Ergebnisse
108
Tabelle 2 Fettsäuren in den Studien (Rot = Wert erhöht, Blau = Wert erniedrigt, Beige= Wert nicht signifikant, Weiß = Wert nicht bestimmt)
Myristin Myristöl Palmitin Palmitöl Stearin Öl Vaccen Linol g-Linolen a-Linolen Eicosen Eicosadien
Dihomo-g-Linol Arachidon Eicosapentaen Behen Eruca Docosapentaen Docosahexaen Lignocerin Nervon
14:0 14:1 16:0 16:1 18:0 18:1n-9 18:1n-7 18:2n-6 18:3n-6 18:3n-3 20:1 20:2n-6 20:3n-6 20:4n-6 20:5n-3 22:0 22:1 n-9 22:5n-3 22:6n-3 24:0 24:1n-9
[Studie Nr.]Referenz Studientyp Teilnehm erzahlKompartment Parameter
19Aldámiz-E. 2007 Querschnitt 83 Fettgewebe Glucose, Insulin, HOMA-IR nd nd ns nd nd ns nd up up ns nd nd up up nd nd nd nd ns nd nd
21Sjögren 2008 Querschnitt 294 Fettgewebe HOMA-2 nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd
18Williams 2007 Querschnitt 484 Fettgewebe MetS ns nd ns up down ns nd down ns down nd nd nd up up nd nd nd up nd nd
22Roberts 2009 Querschnitt 59 Fettgewebe-TG HOMA-IR down nd up ns down ns nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd
26Pelikanova 1991a Fall-Kontroll 35 Ery PL T2D ns nd ns ns ns ns nd ns ns down nd nd ns up ns down nd ns up up up
12Clifton 1998 Querschnitt 54 Ery totalFA Insulin ns ns ns ns ns ns nd ns nd ns ns ns ns down ns nd ns ns ns ns ns
6Krachler 2007 Prospektiv 450 Total Ery FA T2D Risiko up nd up up up ns nd down nd ns nd nd up ns ns nd nd down down nd nd
37Bakan 2006 Fall-Kontroll 52 Ery-membrane T2D nd nd up nd ns ns nd ns nd nd nd nd nd up nd nd nd nd nd nd nd
34Rodriguez 2004 Fall-Kontroll 56 EryPL T2D ns down ns ns ns ns ns ns nd ns nd ns ns ns ns ns nd ns ns ns ns
37Bakan 2006 Fall-Kontroll 52 Leuko-membrane T2D up nd up nd down up nd ns nd nd nd nd nd down nd nd nd nd nd nd nd
20Kabagambe 2008 Querschnitt 1036 Total Ery FA MetS ns nd up up ns up nd down nd ns nd nd nd ns ns nd nd ns up nd nd
4Warensjö 2005 Prospektiv 1360 Serum CE MetS Risiko up nd up up nd up nd down up ns nd nd up ns ns nd nd nd ns nd nd
1Vessby 1994 Prospektiv 1828 Serum CE T2D Risiko up nd ns up ns ns nd down up ns nd nd up ns ns nd nd nd ns nd nd
3Wang 2003 Prospektiv 2902 Serum CE T2D Risiko nd nd up up up ns nd down up ns nd nd up ns ns nd nd nd ns nd nd
29Seigneur 1994 Fall-Kontroll 49 Serum CE T2D ns nd ns ns ns ns ns ns ns ns nd ns ns ns nd ns nd ns nd ns ns
26Pelikanova 1991a Fall-Kontroll 35 Serum CE T2D ns nd ns ns ns ns nd down down down nd nd ns up ns nd nd nd nd nd nd
28Ratzmann 1991 Fall-Kontroll 43 Serum CE T2D nd nd up ns nd nd nd ns nd nd nd nd nd ns ns nd nd nd nd nd nd
33Yang 2004 Fall-Kontroll 101 Serum CE T2D ns nd up ns up up up ns down down nd ns down down down ns nd down down ns nd
10Vessby Diabetologia 1994Querschnitt 218 Serum CE hyperins. clamp nd nd up up ns ns nd down up ns nd nd up up ns nd nd nd ns nd nd
13Barned-Lewis 2000Querschnitt 81 Serum CE hyperins. clamp, Insulin nd nd up up ns ns nd down ns ns nd nd up ns nd nd nd nd nd nd nd
8Salomaa 1990 Querschnitt 520 Serum CE Glucoseintoleranz ns nd up up ns ns nd down up down nd nd up up ns nd nd nd ns nd nd
14Lovejoy 2001 Querschnitt 38 Serum CE HOMA-IR up nd ns up ns ns nd ns ns ns nd nd up ns up nd nd nd nd nd nd
23Kawashima 2009 Querschnitt 94 Plasma CE MetS nd nd ns up ns up nd down up ns nd nd ns ns ns nd nd nd ns nd nd
26Pelikanova 1991a Fall-Kontroll 35 Serum FFA T2D ns nd ns ns ns ns nd ns ns ns nd nd ns down nd nd nd nd nd nd nd
33Yang 2004 Fall-Kontroll 101 Serum FFA T2D ns nd ns ns ns up up ns ns down nd down ns ns up ns nd up up ns nd
3Wang 2003 Prospektiv 2902 Serum PL T2D Risiko nd nd up ns up down nd down ns down nd nd up ns ns nd nd nd ns nd nd
5Hodge 2007 Prospektiv 3737 Serum PL T2D Risiko nd nd ns up up ns nd down nd ns nd nd up up up nd nd ns up nd nd
32Pelikanova 2001 Fall-Kontroll 77 Serum PL T2D ns nd down ns down ns nd down ns down nd nd up up up nd nd down up ns up
29Seigneur 1994 Fall-Kontroll 49 Serum PL PhosphatidyylcholineT2D ns nd ns ns ns ns ns ns nd nd ns ns ns ns nd nd ns nd nd ns ns
29Seigneur 1994 Fall-Kontroll 49 Serum PL SphingomyelinT2D ns nd ns ns ns ns ns ns nd nd nd nd up ns nd ns nd nd nd down ns
34Rodriguez 2004 Fall-Kontroll 56 Serum PL T2D down nd ns ns ns ns ns ns nd ns nd ns ns ns ns ns nd ns ns ns ns
28Ratzmann 1991 Fall-Kontroll 43 Serum PL T2D nd nd up nd nd ns nd down nd nd nd nd nd ns ns nd nd nd nd nd nd
35Rodriguez PLEF 2004Fall-Kontroll 49 Serum PL T2D ns nd ns ns ns ns down ns nd ns nd ns ns up ns nd nd up up down down
26Pelikanova 1991a Fall-Kontroll 35 Serum PL T2D ns nd ns up ns ns nd down down ns nd nd up up ns ns nd ns up ns ns
33Yang 2004 Fall-Kontroll 101 Serum PL T2D up nd ns up ns up up ns ns ns nd ns down ns down ns nd down down down nd
38Maruyama 2008 Fall-Kontroll 165 Serum PL MetS ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns
25Huang 2010 Querschnitt 929 Plasma PL MetS nd nd nd nd nd nd nd nd nd ns nd nd nd down down nd nd down down nd nd
7Pelikanova 1989 Querschnitt 11 Serum PL hyperins. clamp, OGTT ns nd up ns ns ns nd down ns ns nd nd ns ns ns ns nd up ns ns ns
30Das 1995 Fall-Kontroll 84 Serum PL T2D nd nd ns nd ns ns nd ns ns down nd nd down down ns nd nd ns down nd nd
26Pelikanova 1991a Fall-Kontroll 35 Serum TG T2D ns nd ns ns down ns nd ns nd down nd nd ns ns nd nd nd nd nd nd nd
29Seigneur 1994 Fall-Kontroll 49 Serum TG T2D ns nd ns ns ns up ns ns nd ns ns ns nd ns nd ns nd nd nd ns ns
28Ratzmann 1991 Fall-Kontroll 43 Serum TG T2D nd nd ns ns nd ns nd ns nd nd nd nd nd ns nd nd nd nd nd nd nd
33Yang 2004 Fall-Kontroll 101 Serum TG T2D down nd ns ns ns ns ns ns ns down nd ns ns ns ns ns nd ns ns ns nd
27Pelikanova 1991b Fall-Kontroll 25 Serum TG T2D ns nd ns ns ns ns nd ns ns ns nd nd ns ns nd nd nd nd nd nd nd
24Kotronen 2009 Querschnitt 16 Serum VLDL HOMA-IR ns ns up ns up ns ns down down down nd nd nd ns ns nd nd ns ns nd nd
15Tremblay 2004 Querschnitt 97 Serum TG Insulin, OGTT ns nd up ns ns down nd ns down ns nd nd nd nd nd nd nd nd nd nd nd
2Laaksonen 2002 Prospektiv 895 Serum Total T2D/IGT Risiko nd nd up nd nd nd nd down nd nd nd nd nd nd nd nd nd nd nd nd nd
16Galgani 2007 Querschnitt 16 Serum Total Insulinsuppressionstest nd nd nd nd ns ns nd ns nd ns nd nd nd down ns nd nd nd ns nd nd
31Bohov 1997 Fall-Kontroll 146 Serum Total T2D ns nd up ns down up ns down ns down nd nd down down ns nd nd ns ns nd nd
37Bakan 2006 Fall-Kontroll 52 Serum Total T2D nd nd up nd down ns nd ns nd nd nd nd nd up nd nd nd nd down nd nd
36Leskinen 2005 Fall-Kontroll 80 Serum Total MetS ns nd up ns ns up nd down ns ns nd nd ns ns ns nd nd ns ns nd nd
24Kotronen 2009 Querschnitt 16 Serum Total HOMA-IR ns ns up up ns up ns down ns ns nd nd nd ns ns nd nd ns ns nd nd
39Nigam 2009 Fall-Kontroll 734 Serum Total MetS ns nd up up up ns nd ns up ns nd nd up ns down nd nd ns down nd nd
17Kusunoki 2007 Querschnitt 93 Serum Total HOMA-IR (vs FA in µg/ml) up nd up up up up nd ns ns ns ns up up ns ns ns up up ns ns ns
11Pan 1994 Querschnitt 52 Muskel PL hyperins. clamp, Insulin nd nd ns up ns ns nd up nd nd nd nd up down nd nd nd nd ns nd nd
9Borkman 1993 Querschnitt 27 Muskel PL Insulin nd nd ns ns down ns nd up nd nd nd nd up down ns nd nd down ns nd nd
9Borkman 1993 Querschnitt 13 Muskel PL hyperins. clamp nd nd ns ns ns up nd ns nd nd nd nd ns down ns nd nd ns ns nd nd
10Vessby Diabetologia 1994Querschnitt 218 Muskel PL hyperins. clamp nd nd up ns ns ns nd ns ns ns nd nd ns ns ns nd nd ns ns nd nd
19Aldámiz-E. 2007 Querschnitt 83 Muskel PL Glucose, Insulin, HOMA-IR nd nd ns nd ns down nd ns ns ns nd nd ns ns nd nd nd nd ns nd nd
10Vessby 1994 Querschnitt 218 Muskel TG hyperins. clamp nd nd up ns ns ns nd ns ns ns nd nd ns ns ns nd nd ns ns nd nd
109
Tabelle 3 Desaturasen, SFAs, MUFAs, PUFAs, Desaturase-Index
D5D D6D D9D SFA MUFA PUFA PUFAn-6 PUFAn-3
C20-22 PUFA
Desaturations-Index
[Studien Nr.]Referenz Studientyp Teilnehmerzahl Kompartment Parameter
19Aldámiz-E. 2007 Querschnitt 83 Fettgewebe Glucose, Insulin, HOMA-IR ns nd nd nd ns ns ns ns nd nd
21Sjögren 2008 Querschnitt 294 Fettgewebe HOMA-2 ns ns up nd nd nd nd nd nd nd
18Williams 2007 Querschnitt 484 Fettgewebe MetS nd nd nd nd nd nd nd nd nd nd
22Roberts 2009 Querschnitt 59 Fettgewebe-TG HOMA-IR nd nd up nd nd nd nd nd nd nd
26Pelikanova 1991a Fall-Kontroll 35 Ery PL T2D nd nd nd ns ns ns ns ns nd nd
12Clifton 1998 Querschnitt 54 Ery totalFA Insulin down nd nd up nd nd down ns down nd
6Krachler 2007 Prospektiv 450 Total Ery FA T2D Risiko down up up up up down nd nd nd nd
37Bakan 2006 Fall-Kontroll 52 Ery-membrane T2D nd nd nd up nd nd nd nd nd down
34Rodriguez 2004 Fall-Kontroll 56 EryPL T2D nd nd nd ns ns ns ns ns nd nd
37Bakan 2006 Fall-Kontroll 52 Leuko-membrane T2D nd nd nd up nd nd nd nd nd down
20Kabagambe 2008 Querschnitt 1036 Total Ery FA MetS nd nd nd up up down down up nd down
4Warensjö 2005 Prospektiv 1360 Serum CE MetS Risiko down up up nd nd nd nd nd nd nd
1Vessby 1994 Prospektiv 1828 Serum CE T2D Risiko nd nd nd nd nd nd nd nd nd nd
3Wang 2003 Prospektiv 2902 Serum CE T2D Risiko nd nd nd up up down nd nd nd nd
29Seigneur 1994 Fall-Kontroll 49 Serum CE T2D ns nd nd ns ns ns nd nd nd nd
26Pelikanova 1991a Fall-Kontroll 35 Serum CE T2D nd nd nd ns ns ns ns down nd nd
28Ratzmann 1991 Fall-Kontroll 43 Serum CE T2D nd nd nd nd nd nd nd nd nd nd
33Yang 2004 Fall-Kontroll 101 Serum CE T2D nd nd nd nd nd nd nd nd nd nd
10Vessby 1994a Querschnitt 218 Serum CE hyperins. clamp nd nd nd nd nd nd nd nd nd nd
13Barned-Lewis 2000 Querschnitt 81 Serum CE hyperins.clamp, Insulin nd nd nd nd nd nd nd nd nd nd
8Salomaa 1990 Querschnitt 520 Serum CE Glucoseintoleranz down up up up up nd down ns nd nd
14Lovejoy 2001 Querschnitt 38 Serum CE HOMA-IR nd nd nd nd nd nd nd nd nd nd
23Kawashima 2009 Querschnitt 94 Plasma CE MetS down up up nd nd nd nd nd nd nd
26Pelikanova 1991a Fall-Kontroll 35 Serum FFA T2D nd nd nd ns ns ns ns nd nd nd
33Yang 2004 Fall-Kontroll 101 Serum FFA T2D nd nd nd nd nd nd nd nd nd nd
3Wang 2003 Prospektiv 2902 Serum PL T2D Risiko nd nd nd up down ns nd nd nd nd
5Hodge 2007 Prospektiv 3737 Serum PL T2D Risiko nd nd nd up ns down down up nd nd
32Pelikanova 2001 Fall-Kontroll 77 Serum PL T2D ns ns ns down up nd up ns nd nd
29Seigneur 1994 Fall-Kontroll 49 Serum PL PhosphatidyylcholineT2D ns nd nd up ns down nd nd nd nd
29Seigneur 1994 Fall-Kontroll 49 Serum PL Sphingomyelin T2D ns nd nd ns ns ns nd nd nd nd
34Rodriguez 2004 Fall-Kontroll 56 Serum PL T2D nd nd nd ns ns ns ns ns nd nd
28Ratzmann 1991 Fall-Kontroll 43 Serum PL T2D nd nd nd nd nd nd nd nd nd nd
35Rodriguez PLEF 2004 Fall-Kontroll 49 Serum PL T2D nd nd nd ns ns up ns up nd nd
26Pelikanova 1991a Fall-Kontroll 35 Serum PL T2D nd nd nd ns ns ns ns ns nd nd
33Yang 2004 Fall-Kontroll 101 Serum PL T2D nd nd nd nd nd nd nd nd nd nd
38Maruyama 2008 Fall-Kontroll 165 Serum PL MetS down ns ns nd nd nd nd nd nd nd
25Huang 2010 Querschnitt 929 Plasma PL MetS nd nd nd ns up down down down nd nd
7Pelikanova 1989 Querschnitt 11 Serum PL hyperins. clamp, OGTT nd nd nd up ns down down ns nd nd
30Das 1995 Fall-Kontroll 84 Serum PL T2D ns ns nd nd nd nd nd nd nd nd
26Pelikanova 1991 Fall-Kontroll 35 Serum TG T2D nd nd nd ns ns ns ns nd nd nd
29Seigneur 1994 Fall-Kontroll 49 Serum TG T2D ns nd nd ns up ns nd nd nd nd
28Ratzmann 1991 Fall-Kontroll 43 Serum TG T2D nd nd nd nd nd nd nd nd nd nd
33Yang 2004 Fall-Kontroll 101 Serum TG T2D nd nd nd nd nd nd nd nd nd nd
27Pelikanova 1991a Fall-Kontroll 25 Serum TG T2D nd nd nd ns ns ns ns nd nd nd
24Kotronen 2009 Querschnitt 16 Serum VLDL HOMA-IR nd nd nd nd nd nd nd nd nd nd
15Tremblay 2004 Querschnitt 97 Serum TG Insulin, OGTT nd nd nd nd nd nd nd nd nd nd
2Laaksonen 2002 Prospektiv 895 Serum Total T2D/IGT Risiko nd nd nd ns nd nd nd nd nd nd
16Galgani 2007 Querschnitt 16 Serum Total Insulinsuppressionstest nd nd ns ns ns nd ns ns nd nd
31Bohov 1997 Fall-Kontroll 146 Serum Total T2D nd nd nd up up nd down ns down nd
37Bakan 2006 Fall-Kontroll 52 Serum Total T2D nd nd nd nd nd nd nd nd nd nd
36Leskinen 2005 Fall-Kontroll 80 Serum Total MetS nd up nd nd nd nd nd nd nd nd
24Kotronen 2009 Querschnitt 16 Serum Total HOMA-IR nd nd nd nd nd nd nd nd nd nd
39Nigam 2009 Fall-Kontroll 734 Serum Total MetS nd nd nd up nd nd up down nd nd
17Kusunoki 2007 Querschnitt 93 Serum Total HOMA-IR nd nd nd nd nd nd ns ns nd nd
11Pan 1994 Querschnitt 52 Muskel PL hyperins. clamp, Insulin down nd ns nd nd nd nd nd down down
9Borkman 1993 Querschnitt 27 Muskel PL Insulin down nd nd ns ns nd ns ns down down
9Borkman 1993 Querschnitt 13 Muskel PL hyperins. clamp down nd nd ns up nd ns ns down down
10Vessby 1994a Querschnitt 218 Muskel PL hyperins. clamp ns nd nd nd nd nd nd ns nd nd
19Aldámiz-E. 2007 Querschnitt 83 Muskel PL Glucose, Insulin, HOMA-IR ns nd nd nd ns ns ns ns nd nd
10Vessby 1994a Querschnitt 218 Muskel TG hyperins. clamp ns nd nd nd nd nd nd ns nd nd
110